Gå till forskningen.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för CIGB-300. Visa hela publikationsregistret

En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publikationer i urvalet

12 träffar

Bibliografisk träff 2014-12-03

Bio-analytical method based on MALDI-MS analysis for the quantification of CIGB-300 anti-tumor peptide in human plasma.

Cabrales-Rico A, de la Torre BG, Garay HE, Machado YJ, Gómez JA, Audain E, Morales O, Besada V, Marcelo JL, Reyes V, Perera Y, Perea SE, Reyes O, González LJ.

J Pharm Biomed Anal · journal article · DOI 10.1016/j.jpba.2014.11.043

Bibliografisk träff 2014-07-08

Synergistic interactions of the anti-casein kinase 2 CIGB-300 peptide and chemotherapeutic agents in lung and cervical preclinical cancer models.

Perera Y, Toro ND, Gorovaya L, Fernandez-DE-Cossio J, Farina HG, Perea SE.

Mol Clin Oncol · research-article; journal article · DOI 10.3892/mco.2014.338

Bibliografisk träff 2014-04-28

Mechanisms of cellular uptake, intracellular transportation, and degradation of CIGB-300, a Tat-conjugated peptide, in tumor cell lines.

Benavent Acero FR, Perera Negrin Y, Alonso DF, Perea SE, Gomez DE, Farina HG.

Mol Pharm · research support, non-u.s. gov't; journal article · DOI 10.1021/mp4006062

Bibliografisk träff 2014-01-01

Targeting chronic lymphocytic leukemia using CIGB-300, a clinical-stage CK2-specific cell-permeable peptide inhibitor.

Martins LR, Perera Y, Lúcio P, Silva MG, Perea SE, Barata JT.

Oncotarget · research support, non-u.s. gov't; research-article; journal article · DOI 10.18632/oncotarget.1513

Bibliografisk träff 2012-03-08

Sensitivity of tumor cells towards CIGB-300 anticancer peptide relies on its nucleolar localization.

Perera Y, Costales HC, Diaz Y, Reyes O, Farina HG, Mendez L, Gómez RE, Acevedo BE, Gomez DE, Alonso DF, Perea SE.

J Pept Sci · research support, non-u.s. gov't; journal article · DOI 10.1002/psc.1432

Bibliografisk träff 2011-07-07

CIGB-300, a synthetic peptide-based drug that targets the CK2 phosphoaceptor domain. Translational and clinical research.

Perea SE, Baladron I, Garcia Y, Perera Y, Lopez A, Soriano JL, Batista N, Palau A, Hernández I, Farina H, Garcia I, Gonzalez L, Gil J, Rodriguez A, Solares M, Santana A, Cruz M, Lopez M, Valenzuela C, Reyes O, López-Saura PA, González CA, Diaz A, Castellanos L, Sanchez A, Betancourt L, Besada V, González LJ, Garay H, Gómez R, Gómez DE, Alonso DF, Perrin P, Renualt JY, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem · research support, non-u.s. gov't; clinical trial, phase i; journal article · DOI 10.1007/s11010-011-0950-y

Bibliografisk träff 2011-05-01

CIGB-300, a proapoptotic peptide, inhibits angiogenesis in vitro and in vivo.

Farina HG, Benavent Acero F, Perera Y, Rodríguez A, Perea SE, Castro BA, Gomez R, Alonso DF, Gomez DE.

Exp Cell Res · research support, non-u.s. gov't; journal article · DOI 10.1016/j.yexcr.2011.04.011

Bibliografisk träff 2010-10-01

Proteomic profile regulated by the anticancer peptide CIGB-300 in non-small cell lung cancer (NSCLC) cells.

Rodríguez-Ulloa A, Ramos Y, Gil J, Perera Y, Castellanos-Serra L, García Y, Betancourt L, Besada V, González LJ, Fernández-de-Cossio J, Sanchez A, Serrano JM, Farina H, Alonso DF, Acevedo BE, Padrón G, Musacchio A, Perea SE.

J Proteome Res · research support, non-u.s. gov't; journal article · DOI 10.1021/pr100728v

Bibliografisk träff 2009-05-13

Safety and preliminary efficacy data of a novel casein kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies.

Solares AM, Santana A, Baladrón I, Valenzuela C, González CA, Díaz A, Castillo D, Ramos T, Gómez R, Alonso DF, Herrera L, Sigman H, Perea SE, Acevedo BE, López-Saura P.

BMC Cancer · clinical trial; research support, non-u.s. gov't; research-article; journal article · DOI 10.1186/1471-2407-9-146

Bibliografisk träff 2009-05-05

Anticancer peptide CIGB-300 binds to nucleophosmin/B23, impairs its CK2-mediated phosphorylation, and leads to apoptosis through its nucleolar disassembly activity.

Perera Y, Farina HG, Gil J, Rodriguez A, Benavent F, Castellanos L, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-08-1056

Bibliografisk träff 2008-06-25

CIGB-300, a novel proapoptotic peptide that impairs the CK2 phosphorylation and exhibits anticancer properties both in vitro and in vivo.

Perea SE, Reyes O, Baladron I, Perera Y, Farina H, Gil J, Rodriguez A, Bacardi D, Marcelo JL, Cosme K, Cruz M, Valenzuela C, López-Saura PA, Puchades Y, Serrano JM, Mendoza O, Castellanos L, Sanchez A, Betancourt L, Besada V, Silva R, López E, Falcón V, Hernández I, Solares M, Santana A, Díaz A, Ramos T, López C, Ariosa J, González LJ, Garay H, Gómez D, Gómez R, Alonso DF, Sigman H, Herrera L, Acevedo B.

Mol Cell Biochem · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1007/s11010-008-9814-5

Bibliografisk träff 2008-01-01

Systemic administration of a peptide that impairs the protein kinase (CK2) phosphorylation reduces solid tumor growth in mice.

Perera Y, Farina HG, Hernández I, Mendoza O, Serrano JM, Reyes O, Gómez DE, Gómez RE, Acevedo BE, Alonso DF, Perea SE.

Int J Cancer · research support, non-u.s. gov't; journal article · DOI 10.1002/ijc.23013